Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Alimera Sciences Inc (ALIM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 75,686
  • Shares Outstanding, K 70,079
  • Annual Sales, $ 35,910 K
  • Annual Income, $ -22,000 K
  • 36-Month Beta 2.17
  • Price/Sales 2.20
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.04
  • Number of Estimates 2
  • High Estimate -0.03
  • Low Estimate -0.04
  • Prior Year -0.10
  • Growth Rate Est. (year over year) +60.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.80 +35.00%
on 01/22/19
1.15 -6.09%
on 02/13/19
+0.23 (+27.06%)
since 01/15/19
3-Month
0.72 +50.42%
on 12/31/18
1.15 -6.09%
on 02/13/19
+0.08 (+8.00%)
since 11/15/18
52-Week
0.72 +50.42%
on 12/31/18
1.34 -19.40%
on 02/28/18
-0.11 (-9.24%)
since 02/15/18

Most Recent Stories

More News
Alimera Sciences Announces Approval for ILUVIEN(R) in Lebanon

Lebanon will be the second Middle Eastern country to approve ILUVIEN

ALIM : 1.08 (unch)
Ocular Inflammation Treatment Market is set to Grow US$ 500 Billion by 2024

New York, January 16, 2019: The is expected to exceed more than US$ 500 Billion by 2024 at a CAGR of 6% in the given forecast period.

VRX.TO : 30.80 (-3.33%)
ALIM : 1.08 (unch)
AGN : 139.07 (+0.29%)
NVS : 89.88 (+0.97%)
AKRX : 4.44 (+2.54%)
PFE : 42.40 (+1.02%)
Alimera Sciences Affirms Record 2018 Revenues

Anticipates 2018 GAAP Net Revenue in Excess of $45 Million

ALIM : 1.08 (unch)
Ocular Inflammation Treatment Market Forecast to Touch US$ 500 Billion by 2024

New York, January 3, 2019: The is expected to exceed more than US$ 500 Billion by 2024 at a CAGR of 6% in the given forecast period.

VRX.TO : 30.80 (-3.33%)
ALIM : 1.08 (unch)
AGN : 139.07 (+0.29%)
NVS : 89.88 (+0.97%)
AKRX : 4.44 (+2.54%)
PFE : 42.40 (+1.02%)
Ophthalmology Disease & Epidemiology Overview 2018 Featuring Alimera Sciences, Allergan, Regeneron, Bayer, Santen, Roche, Genentech, & Novartis - ResearchAndMarkets.com

The "Ophthalmology - Disease & Epidemiology Overview" report from Decision Resources Group has been added to ResearchAndMarkets.com's offering.

ALIM : 1.08 (unch)
AGN : 139.07 (+0.29%)
NVS : 89.88 (+0.97%)
Alimera Sciences Announces Pricing Approval For ILUVIEN(R) in the U.A.E.

The U.A.E. becomes the first country in the Middle East to obtain pricing approval

ALIM : 1.08 (unch)
Alimera Sciences Appoints Rick Eiswirth as Chief Executive Officer

ALIM : 1.08 (unch)
Alimera Sciences Announces Canadian Regulatory Approval for ILUVIEN(R)

ATLANTA, GA / ACCESSWIRE / November 26, 2018 / Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced...

ALIM : 1.08 (unch)
Consolidated Research: 2018 Summary Expectations for Texas Instruments, Sino-Global Shipping America, Alimera Sciences, Sypris Solutions, JetPay, and Performant Financial -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Texas Instruments Incorporated...

SINO : 0.90 (+5.88%)
ALIM : 1.08 (unch)
JTPY : 5.04 (-0.20%)
PFMT : 2.42 (+10.50%)
TXN : 107.57 (+0.56%)
SYPR : 1.01 (-6.48%)
Alimera Sciences to Present at Upcoming Investor Conferences

ATLANTA, GA / ACCESSWIRE / November 9, 2018 / Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced...

ALIM : 1.08 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade ALIM with:

Business Summary

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes...

See More

Key Turning Points

2nd Resistance Point 1.16
1st Resistance Point 1.12
Last Price 1.08
1st Support Level 1.05
2nd Support Level 1.02

See More

52-Week High 1.34
Fibonacci 61.8% 1.10
Last Price 1.08
Fibonacci 50% 1.03
Fibonacci 38.2% 0.96
52-Week Low 0.72

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar